Acquisition extends OraSure’s leadership position in the microbiome services industry BETHLEHEM, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding equity of Diversigen in an all-cash transaction. Diversigen…
Nature Communications publishes new research from Joseph Petrosino, PhD, Diversigen Founder and Chief Science Officer, and other leading researchers. Using multidisciplinary approaches, the research report shows that a complex interplay between human milk oligosaccharid[es (HMOs), milk microbiome, and infant gut microbiome impacts neonatal rotavirus infections.
Diversigen will serve as a central lab for the generation of high quality microbiome data to be incorporated into the Crohn’s & Colitis Foundation’s IBD Plexus® platform.
Topping the 11th annual list is the harnessing of the microbiome, the gut bacteria swarming in all of us. Recent discoveries have revealed the power of microbes to prevent, diagnose and treat disease. The healthcare industry will soon be pouring resources into addressing the potential for new therapies, diagnostics, probiotics and other products.
Phase I Clinical Trial Generates Data on Mechanism of Action, Safety and Tolerability
4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on the phase 1 clinical trial in respect of Blautix, its proprietary single strain live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).
“Metanome, Inc. has been a valuable corporate collaborator in our studies of the human microbiome delivering high-quality, genomic data in a timely manner. I’ve appreciated their responsiveness and willingness to work with Seres Health on meeting our various genomic characterization needs and look forward to continuing to work with Metanome to support our future sequencing efforts.” – Dr. Matthew Henn, Head of Therapeutic Design at Seres Health
Researchers have traveled to the ends of the earth in search of exotic microorganisms that can produce the medicine we need to live and thrive. But as a new study points out, we may have overlooked an extremely rich source of drugs that was right under our noses: bacteria in and on the human body.
Scientists have long studied the link between our genes and our health. Now, in a growing area of scientific research, they’re studying the link between the bacteria in our intestines and virtually every disease that ails us.
Scientists analyzing the gut microbiome have found groups of bacteria that are either abundant or nearly absent – a finding that could aid in coming up with ways to intervene to improve a person’s health. Though there is gradual variation in the abundance of much of gut bacteria, the scientists said in this week’s issue of the journal Nature Communications, specific bacterial groups exist in stable configurations that are associated with a person’s physiology and health.
Architectural design has the potential to influence the microbiology of the built environment, with implications for human health and well-being, but the impact of design on the microbial biogeography of buildings remains poorly understood. In this study we combined microbiological data with information on the function, form, and organization of spaces from a classroom and office building to understand how design choices influence the biogeography of the built environment microbiome.